Dr. Adithya Hari Joins Pennington Biomedical as Physician/Nuclear Oncologist, Driving Strategic Growth in Cancer Metabolism Program

Pennington Biomedical Research Center proudly announces the appointment of Dr. Adithya Hari, MD, as Assistant Professor and Physician/Nuclear Oncologist within its Division of Clinical Science, effective April 21. This strategic recruitment marks a pivotal expansion in Pennington Biomedical’s capabilities, particularly in the intersecting fields of cancer metabolism and nuclear medicine. The endeavor was executed in strong collaboration with significant regional partners including Mary Bird Perkins Cancer Center, Louisiana Cancer Research Center, and LSU Health New Orleans, reflecting a multi-institutional commitment to advancing oncologic research and treatment in Louisiana.

Dr. Hari’s arrival signifies a transformative step in the deployment of precision oncology in the region, as he brings a specialized expertise in nuclear oncology combined with translational science aimed at deciphering metabolic processes in cancer progression. Pennington Biomedical’s Executive Director, Dr. John Kirwan, emphasized that this addition reflects “a deep investment in the future of cancer research and patient-centered innovation,” positioning the center to compete for the esteemed National Cancer Institute (NCI) Cancer Center designation. This classification would elevate Louisiana’s status as a national leader in cancer research, leveraging Dr. Hari’s integrated clinical and laboratory research skills.

In his new role, Dr. Hari will spearhead a research program centered on nuclear medicine, an area that has seen remarkable breakthroughs through the discovery and development of theranostic agents. These agents—capable of both diagnostic imaging and targeted therapeutic delivery—offer unparalleled promise to millions of cancer patients by enhancing treatment specificity and efficacy. His research promises to deepen understanding of cancer metabolism pathways and facilitate the design of precision therapeutics that exploit metabolic vulnerabilities within tumors.

The field of nuclear oncology, where Dr. Hari’s expertise lies, is at the forefront of clinical innovation. It combines radiopharmaceuticals that deliver radioactive isotopes directly to cancer cells, enabling highly selective tumor imaging and destruction while sparing healthy tissue. This approach exemplifies the principles of precision medicine, targeting molecular and metabolic aberrations unique to individual patients’ tumors, which may revolutionize outcomes for various cancer types, including those traditionally resistant to conventional therapies.

Beyond the laboratory, Dr. Hari will dedicate a significant portion of his efforts to direct patient care through a clinical partnership with Mary Bird Perkins Cancer Center. This collaboration enhances the translational impact of his work, ensuring that laboratory discoveries rapidly inform clinical protocols and patient treatment strategies. Jodi Conachen, Chief Operating Officer at Mary Bird Perkins, recognized Dr. Hari’s leadership as integral to elevating oncology treatment standards, underscoring the importance of institutional collaboration in expanding access to cutting-edge cancer care.

As a member of the Louisiana Cancer Research Center (LCRC), Dr. Hari will integrate his nuclear medicine initiatives with ongoing statewide efforts to combat cancer’s burden. LCRC functions as a hub uniting over 200 researchers from universities and medical centers, including LSU Health New Orleans, Tulane University School of Medicine, Xavier University of Louisiana, and Ochsner Health, fostering interdisciplinary research that spans basic science to clinical applications. This network aims to accelerate cancer prevention research, early detection methods, and the transition of novel treatments into clinical settings.

His work will also support the LSU-led preparations for the forthcoming submission of the NCI Cancer Center Support Grant, a critical milestone in securing additional funding and resources to scale cancer research infrastructure in Louisiana. Collaborators such as Sven Davisson, LCRC’s Chief Administrative Officer, highlighted that Dr. Hari’s specialized knowledge in nuclear medicine will enhance the center’s research capabilities and clinical offerings, ultimately driving systemic improvements in cancer care across the state.

Dr. Hari’s academic and professional background is robust and multidisciplinary, positioning him well to impact precision oncology deeply. He received his medical degree from Kurnool Medical College, India, before pursuing doctoral studies in Clinical and Translational Science at Case Western Reserve University. Most notably, he completed a prestigious Nuclear Oncology Fellowship at Memorial Sloan Kettering Cancer Center, a global leader in cancer research and treatment. This fellowship equipped him with advanced training in radiopharmaceutical development, clinical trial execution, and molecular imaging techniques.

At Pennington Biomedical, known for its cutting-edge research into chronic diseases such as obesity, diabetes, cardiovascular disease, cancer, and dementia, Dr. Hari will join a vibrant ecosystem of over 600 research professionals engaged in clinical, population, and basic science investigations. The center’s infrastructure supports high-throughput technologies and state-of-the-art core facilities enabling interdisciplinary approaches to elucidate complex biological phenomena underpinning metabolic diseases and cancer.

Dr. Lucio Miele, Director of the LSU LCMC Health Cancer Center, articulated enthusiasm about Dr. Hari’s arrival, spotlighting the synergistic collaboration spanning multiple Louisiana institutions. This coalition embodies a model of cooperative science and clinical advancement, aiming to accelerate breakthroughs in cancer prevention, early detection, and therapeutics. In uniting research and clinical expertise across Pennington Biomedical, Mary Bird Perkins, LSU LCMC Health, LSU Health New Orleans, and the Louisiana Cancer Research Center, Louisiana is poised to make significant gains toward reducing cancer morbidity and mortality statewide.

The broader implications of Dr. Hari’s work in nuclear oncology and cancer metabolism cannot be overstated. With precision medicine increasingly becoming the standard of care, the integration of metabolic imaging and targeted radiotherapy holds promise for more personalized, less toxic, and more effective cancer treatments. As the therapeutic landscape evolves, innovations originating from Dr. Hari’s research may translate into improved survival rates and quality of life for patients, addressing cancers that have historically lacked effective targeted treatments.

Pennington Biomedical’s commitment to this initiative reflects a strategic vision to not only understand disease mechanisms at a cellular and systemic level but also to translate these discoveries into scalable health solutions. Dr. Hari’s expertise strengthens this ambition, bridging the gap between molecular science and patient-centered clinical application, and positioning the center as an epicenter for innovative cancer research and therapy development.

In summary, the recruitment of Dr. Adithya Hari represents a major milestone for Louisiana’s oncology research continuum. His cutting-edge expertise in nuclear oncology and metabolic science, coupled with robust institutional collaborations, sets the stage for transformational advancements in cancer diagnosis, management, and prevention. This integrated approach underlines the promise of precision medicine to tackle one of the world’s deadliest diseases with unprecedented focus and innovation.

News Publication Date: April 21, 2024

Web References:

• Pennington Biomedical Research Center: http://www.pbrc.edu
• Mary Bird Perkins Cancer Center: https://marybird.org/
• Louisiana Cancer Research Center: https://www.louisianacancercenter.org/
• LSU LCMC Health Cancer Center: https://www.medschool.lsuhsc.edu/cancer_center/